⾸席執⾏官致辭

GEXVal Inc. started its journey in 2018 at Shonan iPark (Kanagawa, Japan), focusing on research and development of drugs for rare and untreatable diseases.

I have been engaged in drug discovery for over decades, but it was only recently when I attended an international conference for a rare disease sponsored by a patient advocacy group, that I realized the true seriousness of “access to medicine” issues that patients and families of rare disease1) are facing with.  Together with colleagues who share the same thoughts, we spun-off from a pharmaceutical company.

From day one, we have been getting enormous support from various patient advocacy groups, medical professionals, and investors across the globe.  As one united team who share the same goal, we always consider patients and families “first” and committed to address unmet medical needs. In 2021, we established a wholly owned subsidiary in Australia dedicated to clinical development.  We are currently preparing for Ph2 studies.

To date, drug discovery for rare diseases is becoming the mainstream in the pharma industry - more than half of recently approved drugs are for rare diseases.  Yet there is no approved drug for over 90% of rare diseases, meaning that patients and families are still facing serious “access to medicine” issues.

In the bitter reality that there is not enough medicine, we envision the society where people with rare diseases have stress-free access to medicine just like others.  We strive to deliver innovative and life-changing medicines to patients and families who live with rare and untreatable diseases, leaving no one behind.

2024年5月

嘉惟思遠製藥有限公司　 董事長兼總經理

加藤珠蘭

1) Rare disease: Definition varies between countries. Japan (<50,000; <4 in 10,000, with population of 128 Million), US (<200,000;  <6.37 in 10,000 with population of 1400 Million), EU (<250,000; <5 in 10,000 with population of 514 Million).

 

企業理念

VISION & MISSION

Leaving no one behind
GEXVal tackles Access to Medicine

GEXVal is fully committed

to bringing hope and smile to those

who are waiting for better treatment options

Our VISION

For patients and families who live with
Rare and Intractable Diseases

GEXVal always considers patients-first

and strives to deliver innovative and affordable medicines to those who are waiting for
better treatment options

Our MISSION

GEXVal is
Purposed to RepurposeⓇ

shelved drugs for patients and families who live
with
rare and intractable diseases

 

Our STRATEGY

Drugs for Rare Diseases- Still More To Do

 

Definition of “rare disease” varies between countries

    • Japan (<50,000、<4 in 10,000, with population of 128 Million)

    • US (<200,000、<6.37 in 10,000 with population of 1400 Million)

    • EU (<250,000、<5 in 10,000 with population of 514 Million)

 

 

 

> 7000 rare diseases Only 5% have
approved treatments
1/10 affected
by rare diseases		 80% are
genetic disorders
Orphan Drugs
Over 500 in development
> 50% of recent FDA approvals		 Incentives have created
framework and opportunity
for alternative approaches

 

 

公司名称的由来

在藥物研發過程中會衍生出許多的化合物，其中只有少數最終會成為藥物。大多數的化合物在問世之前便遭埋沒，其中不乏仍具有高度研發潛力的化合物。我們透過重新定位研究，找出這些具有再研發潛力的化合物，塑造並賦與其新的價值，即Generate Extra Value，本公司名稱GEXVal也由此而來。

嘉惟思遠
公司名出自古詩詞”任大者思遠，思遠者忘近”，同時取英文名的諧音。寓意我們祈求美好事物，統籌規劃，致力於把創新藥帶給患者的理念。

 

Generate Extra Value

to deliver cost-effective, innovative treatment options to improve health and QoL of patients and families affected by rare and intractable diseases

 

商標的含義

企業的象徵

本公司以日本傳統的裝飾帶“花紙繩”編織的蝴蝶做爲商標圖案。花紙繩是7世紀左右從隋朝傳入日本的，後來在日本獨自發展成了裝飾贈品的飾件。花紙繩的編織法中有一種是用於護身符袋的十字結。結的正面爲“口”字，反面爲“十”字的形狀，兩者合二爲一時，就變成了“葉”字（日文稱爲葉結，有如願以償的繩結之意）。

本公司的願望是早日將藥物交給患者使用。我們的企業象徵中就蘊含著希望如願以償的期許。

企業的顔色

GEXVal的企業顔色是小紫色。本公司之重點專案的對象是罕見疾病的患者群體，其也採用紫色做爲象徵顔色，而且有鑒於本公司的商標圖案爲“細帶閃蛺蝶”（日文發音也是小紫色），因此我們選用小紫色做爲企業顔色。

小紫色與白棠子樹的果實顔色很類似，爲典雅的深紫色，是日本的古典色彩之一，在七世紀中葉的日本書紀中也有相關記載，屬於日本的冠位“七色十三階冠”中的高貴色彩。

 

'Komurasak' Butterfly
Scientific name: Apatura metis substituta

蛺蝶平常翅膀多半是閉合著的，乍看之下是普通的棕色蝴蝶，但是當蛺蝶在下午到傍晚時刻四處活躍飛舞時，雄蛺蝶翅膀內側的鱗片會隨著光線的變化發出鮮艶的紫色光芒，因此被稱爲紫蛺蝶。紫蛺蝶幾乎遍布日本全國各地，上至北海道下至九州。

在本公司辦公室的所在地-神奈川縣也可看到紫蛺蝶的踪跡，其被列入瀕危物種的紅色名錄中。紫蛺蝶的主要棲息地是柳樹自然生長的河川區域，但令人遺憾的是由於城市開發和河川泛濫的關係，紫蛺蝶的個體數量似乎已顯著减少。

'Komurasaki' Plant
Scientific name: Callicarpa dichotoma

分布在臺灣、中國的溫帶至亞熱帶地區，可見於日本本州以南至琉球群島一帶。由於其體積比同屬的紫珠略小，因此被命名爲“小紫珠”。當小紫珠的紫色果實綴滿枝頭時，其晶晶泛彩的模樣更加優美奢華。

衆所皆知10月至11月是小紫珠結果的時期，然而似乎很少有人注意到6月至8月嬌然綻放的淡紫色花朵。

Show more information about GEXVal

會社概要

詳細

團隊

詳細